Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel approach to radioembolization treatment planning using a hybrid [<sup>99m</sup>Tc]Tc-MAA contrast enhanced SPECT/CT.

European journal of nuclear medicine and molecular imaging·2026
Same author

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same author

Fatigue after pediatric bone sarcoma: prevalence and associated factors in pediatric and adult patients and survivors after treatment.

Journal of cancer survivorship : research and practice·2026
Same author

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.

The Lancet. Oncology·2026
Same author

Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [<sup>177</sup>Lu]Lu-DOTATATE: results from the LuDO-N trial.

European journal of nuclear medicine and molecular imaging·2026
Same author

Temporal Trends of Subsequent Malignant Neoplasms in Childhood Cancer Survivors and the Impact of Treatment Changes: A DCCSS-LATER Study.

Journal of the National Cancer Institute·2026

Related Experiment Video

Updated: Jul 8, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Radioligand therapy for paediatric patients with solid tumours.

Leonor Teles1, Nelleke Tolboom1,2, Alex J Poot1,2

  • 1Princess Maxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.

The British Journal of Radiology
|July 7, 2026
PubMed
Summary

Radioligand therapy (RLT) shows promise for treating paediatric solid tumours, offering targeted radiation delivery. Further research is needed to overcome challenges and improve outcomes for children with relapsed or metastatic cancers.

Keywords:
Radioligand therapybrain tumoursneuroblastomaosteosarcomaradiopharmaceuticalssarcomatheranostics

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jul 8, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

  • Paediatric Oncology
  • Nuclear Medicine
  • Targeted Cancer Therapy

Background:

  • Limited progress in treating paediatric solid tumours, especially relapsed/metastatic disease.
  • Current treatments (surgery, chemotherapy, radiotherapy) have significant toxicities.
  • Radioligand therapy (RLT) is a targeted approach with proven adult benefits.

Purpose of the Study:

  • To review current clinical evidence of RLT in paediatric solid tumours.
  • To discuss molecular targets, radiopharmaceuticals, outcomes, and safety.
  • To identify challenges and future directions for RLT in paediatric oncology.

Main Methods:

  • Systematic review of clinical studies on RLT for paediatric solid tumours.
  • Analysis of molecular targets, radiopharmaceuticals, and clinical outcomes.
  • Evaluation of safety profiles and long-term toxicities.

Main Results:

  • RLT shows potential in paediatric solid tumours, notably neuroblastoma.
  • Evidence is fragmented, with small series limiting definitive conclusions.
  • Safety profiles and efficacy require further investigation.

Conclusions:

  • RLT is a promising targeted therapy for paediatric solid tumours.
  • More extensive clinical trials are necessary to establish efficacy and safety.
  • Addressing challenges is crucial for advancing RLT in paediatric oncology.